Middle East & Africa Generic Drugs Market Analysis and Forecast by Size, Share, Growth, Trends 2031
Middle East & Africa Generic Drugs Market Size and Forecast (2021 - 2031) Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Molecule Type (Antidepressants, Antihistamines, Analgesics, Antibiotics, Antivirals, Diuretics, and Other Molecule Types), Indication (Metabolic Diseases, Cancer, Immunology, Respiratory Disorder, Cardiovascular Disorder, Neurology Disorder, Rare Diseases, and Other Indications), Type (Prescription and OTC Drugs), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
- Status : Published
- Report Code : TIPRE00041414
- Category : Life Sciences
- No. of Pages : 200
- Available Report Formats :
The Middle East & Africa generic drugs market size is expected to reach US$ 35,795.50 million by 2031 from US$ 28,684.12 million in 2024. The market is estimated to record a CAGR of 3.2% from 2025 to 2031.
Executive Summary and Middle East & Africa Generic Drugs Market Analysis:The Middle East and Africa (MEA) generic drugs market is experiencing significant growth driven by improved healthcare infrastructure, rising demand for affordable treatments, and an increasing prevalence of chronic diseases such as diabetes, cardiovascular disorders, cancer, and infectious diseases, including malaria, HIV/AIDS, and tuberculosis. Countries such as Saudi Arabia, the UAE, and South Africa are witnessing heightened demand for generic drugs due to the aging population and rising life expectancy, as per the Ageing in the Middle-East and North Africa, with the elderly expected to form the largest age group by 2050 in MENA. Government initiatives promoting cost-effective healthcare solutions, centralized drug procurement, and price control policies are supporting generic drug adoption across the region. Local pharmaceutical manufacturing is expanding in countries including Egypt, Jordan, and South Africa, helping reduce import dependency and enhance regional drug security. International collaborations and public-private partnerships are further fueling innovation and the production of complex generics and biosimilars, positioning MEA as a key region for utilizing generic pharmaceuticals. The growing awareness about preventive healthcare and the increasing number of health insurance schemes are contributing to higher accessibility of medications. Regulatory reforms and faster drug approval processes are enabling quicker market entry for generic drug producers. Companies are also investing in digital transformation, logistics infrastructure, and cold chain networks to improve last-mile delivery and product quality.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Middle East & Africa Generic Drugs Market: Strategic Insights
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Key segments that contributed to the derivation of the Middle East & Africa generic drugs market analysis are molecule type, indication, type, and distribution channel.
- Based on molecule type, the Middle East & Africa generic drugs market is segmented into antidepressants, antihistamines, analgesics, antibiotics, antivirals, diuretics, and others. The antibiotics segment held the largest share of the market in 2024.
- By indication, the Middle East & Africa generic drugs market is segmented into metabolic diseases, cancer, immunology, respiratory disorder, cardiovascular disorder, neurology disorder, rare diseases, and others. The cancer segment held the largest share of the market in 2024.
- Based on type, the Middle East & Africa generic drugs market is bifurcated into prescription and OTC drugs. The prescription segment held a larger share of the market in 2024.
- By indication, the Middle East & Africa generic drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest share of the market in 2024.
According to Living Media India Limited 2025, the expiration of patents on branded drugs significantly drives the pharmaceutical generic drug market. Generic manufacturers can produce and sell bioequivalent versions at significantly lower prices after the patent expiry, creating vast market opportunities. For instance, in 2025-26, key drugs such as Keytruda (developed by Merck for cancer immunotherapy), which generated over US$ 25 billion in sales in 2024, and Ozempic (produced by Novo Nordisk for diabetes and anti-obesity treatment), are set to lose their patents. This initiative will develop new opportunities for generic pharmaceuticals and biosimilars. Other high-revenue drugs, such as Eliquis (Bristol-Myers Squibb's blood thinner) and Cosentyx (Novartis' immunology drug), will face similar patent expirations, further expanding the opportunity for generics.
Several blockbuster drugs are expected to lose their patents in 2024, creating even more space for generic alternatives. Notable drugs include:
- Abilify Maintaina (Otsuka Pharmaceutical), an injectable antipsychotic with US$ 15.5 billion in sales in 2022, is set to lose its patent by October 2024.
- Xarelto (Janssen Pharmaceuticals), a leading anticoagulant, is scheduled to lose its patent in August 2024.
- Farxiga (AstraZeneca), a blockbuster anti-diabetic drug generating ~US$ 4.3 billion annually, will lose its patent in 2024.
- Lynparza (AstraZeneca), used in cancer treatment, with sales of ~US$ 2.7 billion, is also set to lose its patent in 2024.
- Symbicort (AstraZeneca), a respiratory drug, will lose its patent in November 2024.
- Entresto (Novartis), a heart failure treatment generating US$ 2.5 billion in 2022, will lose its patent in May 2024.
- Latuda (Sunovion Pharmaceuticals), an antipsychotic with US$ 1.8 billion in sales, will lose its patent in February 2024.
- Xifaxan (Salix Pharmaceuticals), a gastrointestinal drug with sales of US$ 1.6 billion, will lose its patent in June 2024.
- Cabometyx (Exelixis), used to treat advanced renal cell carcinoma, will lose its patent in September 2024.
These pharmaceuticals collectively generated substantial global revenue and created opportunities for generic manufacturers to develop more cost-effective alternatives. Between 2023 and 2029, patents for over 100 critical drugs, including cancer, diabetes, and cardiovascular drugs, will expire, accounting for more than US$ 300 billion in global annual sales. This loss of exclusivity will significantly expand the market share for generics and biosimilars, reducing healthcare costs worldwide. The influx of generics is expected to reshape the global pharmaceutical landscape by providing more affordable treatment options.
The expiration of patents for high-revenue drugs is anticipated to drive a shift in market dynamics, increasing the affordability and accessibility of healthcare. According to The Indian Express Ltd., 2025, the expiration of patents for these blockbuster drugs will create a surge in generics and biosimilars, providing a substantial growth opportunity for generic drug manufacturers.
Middle East & Africa Generic Drugs Market Country InsightsBased on country, the Middle East & Africa generic drugs market comprises Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. South Africa held the largest share in 2024.
South Africa's generic drugs market is witnessing significant momentum, driven by structural reforms in healthcare, government initiatives, and the need for affordable medication. With a GDP of USUS$ 377.78 billion in 2023, healthcare represented approximately 8.5% of the national GDP-marking it as the second-largest share among sectors. The country is investing in healthcare infrastructure to address key health challenges such as HIV/AIDS, tuberculosis, cancer, and other non-communicable diseases. As per the International Trade Administration (ITA), total prescription drug sales in South Africa amounted to USUS$ 4.514 billion in 2022, of which generic drugs accounted for USUS$ 2.059 billion, indicating a preference for cost-effective treatment options. South Africa's public healthcare system serves nearly 80% of the population, and generics play a vital role in expanding access to essential medicines amid budget constraints. The local market is supported by government-led initiatives such as the National Health Insurance (NHI) scheme, which promotes the use of generics to reduce pharmaceutical expenditure. According to GLOBOCAN 2022 data, 120,226 new cancer cases and 69,874 cancer-related deaths were recorded, underscoring the urgent need for enhanced therapeutic access. The prevalence of chronic diseases such as diabetes and cardiovascular disorders is rising, driven by lifestyle changes and urbanization. In response, South Africa is fostering local pharmaceutical manufacturing, offering incentives to generic drug producers, and simplifying regulatory approval through agencies such as SAHPRA (South African Health Products Regulatory Authority). International pharmaceutical companies are also partnering with local players to boost generic drug availability and reduce import dependency.
Middle East & Africa Generic Drugs Market Company ProfilesSome of the key players operating in the market include Teva Pharmaceutical Industries Ltd, Viatris Inc, Dr. Reddy's Laboratories Ltd, Novartis AG, Sun Pharmaceutical Industries Ltd, AbbVie Inc, AstraZeneca Plc, Sanofi SA, Aurobindo Pharma Ltd, and Glenmark Pharmaceuticals Ltd, among others. These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.
Middle East & Africa Generic Drugs Market Research Methodology:The following methodology has been followed for the collection and analysis of data presented in this report:
Secondary Research
The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:
- Company websites, annual reports, financial statements, broker analyses, and investor presentations.
- Industry trade journals and other relevant publications.
- Government documents, statistical databases, and market reports.
- News articles, press releases, and webcasts specific to companies operating in the market.
All financial data included in the Company Profiles section has been standardized to USD. For companies reporting in other currencies, figures have been converted to USD using the relevant exchange rates for the corresponding year.
Primary Research
The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:
- Validate and refine findings from secondary research.
- Enhance the expertise and market understanding of the analysis team.
- Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects.
Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:
- Industry stakeholders: Vice Presidents, business development managers, market intelligence managers, and national sales managers
- External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:
4. Middle East & Africa Generic Drugs Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Middle East & Africa
4.2.1.1 Saudi Arabia
4.2.1.2 South Africa
4.2.1.3 United Arab Emirates (UAE)
4.3 Top 10 Blockbuster Drugs Facing Patent Expiry in the Next 5 Years with Revenue Data and Market Impact:
4.4 Average Selling Price, 2024
4.5 Pipeline Analysis:
5. Middle East & Africa Generic Drugs Market – Key Market Dynamics
5.1 Middle East & Africa Generic Drugs Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Patent Expiry and Loss of Market Exclusivity:
5.2.2 Government Policies and Regulatory Support for Generics
5.3 Market Restraints
5.3.1 Intense Price Competition and Thin Profit Margins
5.4 Market Opportunities
5.4.1 Increasing Government Initiatives to promote the use of generic drugs
5.5 Future Trends
5.5.1 Rising Popularity of Biosimilars in the Global Generic Drugs Market
5.6 Impact of Drivers and Restraints:
6. Generic Drugs Market – Middle East & Africa Analysis
6.1 Middle East & Africa Generic Drugs Market Revenue (US$ Billion), 2021–2031
6.2 Middle East & Africa Generic Drugs Market Forecast Analysis
7. Middle East & Africa Generic Drugs Market Analysis – by Molecule Type
7.1 Antidepressants
7.1.1 Overview
7.1.2 Antidepressants: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
7.2 Antihistamines
7.2.1 Overview
7.2.2 Antihistamines: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
7.3 Analgesics
7.3.1 Overview
7.3.2 Analgesics: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
7.4 Antibiotics
7.4.1 Overview
7.4.2 Antibiotics: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
7.5 Antivirals
7.5.1 Overview
7.5.2 Antivirals: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
7.6 Diuretics
7.6.1 Overview
7.6.2 Diuretics: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
7.7 Others
7.7.1 Overview
7.7.2 Others: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8. Middle East & Africa Generic Drugs Market Analysis – by Indication
8.1 Metabolic Diseases
8.1.1 Overview
8.1.2 Metabolic Diseases: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.2 Cancer
8.2.1 Overview
8.2.2 Cancer: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.3 Immunology
8.3.1 Overview
8.3.2 Immunology: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.4 Respiratory Disorder
8.4.1 Overview
8.4.2 Respiratory Disorder: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.5 Cardiovascular Disorder
8.5.1 Overview
8.5.2 Cardiovascular Disorder: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.6 Neurology Disorder
8.6.1 Overview
8.6.2 Neurology Disorder: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.7 Rare Disease
8.7.1 Overview
8.7.2 Rare Disease: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.8 Others
8.8.1 Overview
8.8.2 Others: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
9. Middle East & Africa Generic Drugs Market Analysis – by Type
9.1 Prescription
9.1.1 Overview
9.1.2 Prescription: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
9.2 OTC Drugs
9.2.1 Overview
9.2.2 OTC Drugs: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
10. Middle East & Africa Generic Drugs Market Analysis – by Distribution Channel
10.1 Hospital Pharmacies
10.1.1 Overview
10.1.2 Hospital Pharmacies: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
10.2 Retail Pharmacies
10.2.1 Overview
10.2.2 Retail Pharmacies: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
10.3 Online Pharmacies
10.3.1 Overview
10.3.2 Online Pharmacies: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
11. Middle East & Africa Generic Drugs Market – Country Analysis
11.1 Middle East & Africa
11.1.1 Middle East & Africa Generic Drugs Market – Revenue and Forecast Analysis – by Country
11.1.1.1 Middle East & Africa Generic Drugs Market – Revenue and Forecast Analysis – by Country
11.1.1.2 Saudi Arabia: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
11.1.1.2.1 Saudi Arabia: Middle East & Africa Generic Drugs Market Share – by Molecule Type
11.1.1.2.2 Saudi Arabia: Middle East & Africa Generic Drugs Market Share – by Indication
11.1.1.2.3 Saudi Arabia: Middle East & Africa Generic Drugs Market Share – by Type
11.1.1.2.4 Saudi Arabia: Middle East & Africa Generic Drugs Market Share – by Distribution Channel
11.1.1.3 South Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
11.1.1.3.1 South Africa: Middle East & Africa Generic Drugs Market Share – by Molecule Type
11.1.1.3.2 South Africa: Middle East & Africa Generic Drugs Market Share – by Indication
11.1.1.3.3 South Africa: Middle East & Africa Generic Drugs Market Share – by Type
11.1.1.3.4 South Africa: Middle East & Africa Generic Drugs Market Share – by Distribution Channel
11.1.1.4 United Arab Emirates: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
11.1.1.4.1 United Arab Emirates: Middle East & Africa Generic Drugs Market Share – by Molecule Type
11.1.1.4.2 United Arab Emirates: Middle East & Africa Generic Drugs Market Share – by Indication
11.1.1.4.3 United Arab Emirates: Middle East & Africa Generic Drugs Market Share – by Type
11.1.1.4.4 United Arab Emirates: Middle East & Africa Generic Drugs Market Share – by Distribution Channel
11.1.1.5 Rest of Middle East & Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
11.1.1.5.1 Rest of Middle East & Africa: Middle East & Africa Generic Drugs Market Share – by Molecule Type
11.1.1.5.2 Rest of Middle East & Africa: Middle East & Africa Generic Drugs Market Share – by Indication
11.1.1.5.3 Rest of Middle East & Africa: Middle East & Africa Generic Drugs Market Share – by Type
11.1.1.5.4 Rest of Middle East & Africa: Middle East & Africa Generic Drugs Market Share – by Distribution Channel
12. Industry Landscape
12.1 Overview
12.2 Expansion
12.3 New Product Development/ Launch/ Approvals
12.4 Merger and Acquisition/Partnership
12.5 Other Business Strategies
13. Company Profiles
13.1 Teva Pharmaceutical Industries Ltd
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Viatris Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Dr. Reddy's Laboratories Ltd
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Novartis AG
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Sun Pharmaceutical Industries Ltd
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 AbbVie Inc
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 AstraZeneca Plc
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Sanofi SA
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Aurobindo Pharma Ltd
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Glenmark Pharmaceuticals Ltd
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 Glossary of Terms
14.2 About The Insight Partners
List of Tables
Table 1. Middle East & Africa Generic Drugs Market Segmentation
Table 2. Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Table 3. Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Molecule Type
Table 4. Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Indication
Table 5. Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Type
Table 6. Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Distribution Channel
Table 7. Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Country
Table 8. Saudi Arabia: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 9. Saudi Arabia: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 10. Saudi Arabia: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 11. Saudi Arabia: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 12. South Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 13. South Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 14. South Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 15. South Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 16. United Arab Emirates: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 17. United Arab Emirates: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 18. United Arab Emirates: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 19. United Arab Emirates: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 20. Rest of Middle East & Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 21. Rest of Middle East & Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 22. Rest of Middle East & Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 23. Rest of Middle East & Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 24. Glossary of Terms, Generic Drugs Market
List of Figures
Figure 1. Middle East & Africa Generic Drugs Market Segmentation – Country
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Middle East & Africa Generic Drugs Market Revenue (US$ Billion), 2021–2031
Figure 5. Middle East & Africa Generic Drugs Market Share (%) – by Molecule Type (2024 and 2031)
Figure 6. Antidepressants: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 7. Antihistamines: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 8. Analgesics: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 9. Antibiotics: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 10. Antivirals: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 11. Diuretics: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 12. Others: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 13. Middle East & Africa Generic Drugs Market Share (%) – by Indication (2024 and 2031)
Figure 14. Metabolic Diseases: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 15. Cancer: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 16. Immunology: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 17. Respiratory Disorder: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 18. Cardiovascular Disorder: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 19. Neurology Disorder: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 20. Rare Disease: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 21. Others: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 22. Middle East & Africa Generic Drugs Market Share (%) – by Type (2024 and 2031)
Figure 23. Prescription: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 24. OTC Drugs: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 25. Middle East & Africa Generic Drugs Market Share (%) – by Distribution Channel (2024 and 2031)
Figure 26. Hospital Pharmacies: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 27. Retail Pharmacies: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 28. Online Pharmacies: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 29. Middle East & Africa Generic Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 30. Saudi Arabia: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Figure 31. South Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Figure 32. United Arab Emirates: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Figure 33. Rest of Middle East & Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.
Absolutely - analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.
Once your order is successfully placed, you will receive a confirmation email along with your invoice.
• For published reports: You'll receive access to the report within 4-6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.
We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we'll be happy to provide a customized proposal or scope.
The report is available in either PDF format or as an Excel dataset, depending on the license you choose.
The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.
Our payment process is fully secure and PCI-DSS compliant.
We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.
Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we're happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you're considering, and we'll share a personalized quote.
Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report's scope, methodology, customization options, or which license suits you best, we're here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.
Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we'll be happy to assist.
Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we'll ensure the issue is resolved quickly so you can access your report without interruption.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Oct 2025
Anesthesia Machines Market
Size and Forecast (2021 - 2034), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Advanced Anesthesia Machines, Basic Anesthesia Machines, and Consumables), Customer (Small Hospitals & Nursing Home, Standalone Hospitals, Tertiary Care Hospitals, and Hospital Chain), End User (Anaesthesiologists, Critical Care Specialists, and Others), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America)
Oct 2025
Hospital at Home Market
Size and Forecast (2021 - 2034), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Component (Equipment & Devices and Software & Services), Service Type (Acute Care at Home, Chronic Disease Management at Home, Post Acute or Transitional Care, Palliative Care and Hospice Care, and Rehabilitation Services), Delivery Mode (Remote Monitoring and Telehealth, In-person Home Visits, and Hybrid Models), Patient Demographic ( Adult Patients and Pediatric Patients), Indication (Cardiovascular Conditions, Respiratory Diseases, Orthopedic and Post-Surgical Recovery, Infectious Diseases, Neurological Rehabilitation, and Others), Care Provider (Hospitals and Health Systems, Home Health Agencies, Primary Care or Physician Groups, and Private HaH Providers), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America)
Oct 2025
MRI-guided Focused Ultrasound Therapy Market
Size and Forecast (2021 - 2034), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Application (Breast Cancer, Prostate Cancer, Liver Cancer, Pancreatic Cancer, Breast Lifting and Aesthetic Application, Nipple and Areola Preservation, Post Surgical Applications, and Others), End User (Healthcare Facilities, Diagnostic Imaging Centers, and Research Centers), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America)
Oct 2025
Drug Delivery Devices Contract Manufacturing Market
Size and Forecast (2021 - 2034), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Device Type (Infusion Devices and Administration Set, Syringes, Inhalers, Autoinjectors, and Pen Injectors), Service Type (Full-device Manufacturing, Sub-assembly and Components, and Materials-specific Services), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America)
Oct 2025
IVD Devices Contract Manufacturing Market
Size and Forecast (2021 - 2034), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Service Type (Full-device Manufacturing, Sub-assembly and Components, and Materials-specific Services), Device Type (IVD consumables, IVD equipment), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America)
Oct 2025
Gene Therapy CDMO Market
Size and Forecast (2021 - 2034), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Service Type (Drug Development and Manufacturing, Testing and Regulatory Services, and Other Service Types), End User (Pharmaceutical Companies, Biopharmaceutical Companies, and Other End Users), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America)
Oct 2025
RT-PCR Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Reagents & Consumables, Instruments, and Software & Services), Application (Research Application, Clinical Application, and Forensic Application), End user (Hospitals and Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Research Laboratories and Academic Institutes, Forensic Laboratories, and Clinical Research Organizations)
Oct 2025
dPCR Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Reagents & Consumables, Instruments, and Software & Services), Application (Research Application, Clinical Application, and Forensic Application), End user (Hospitals and Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Research Laboratories and Academic Institutes, Forensic Laboratories, and Clinical Research Organizations)
Get Free Sample For